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Background: Serum concentrations of soluble mesothelin-related peptides (SMRP) have been
reported to be higher in patients with malignant mesothelioma than in healthy subjects and
in patients with non-malignant mesothelioma diseases. The aim of the present meta-analysis
was to establish the overall diagnostic accuracy of the measurement of SMRPs for diagnosing
malignant mesothelioma.
Methods: After a systematic review of English language studies, sensitivity, specificity, and
other measures of accuracy of serum SMRPs in the diagnosis of malignant mesothelioma were
pooled using random-effects models. Summary receiver operating characteristic curves were
used to summarize overall test performance.
Results: Eleven publications from 12 studies met our inclusion criteria. The summary estimates
for SMRPs in the diagnosis of malignant mesothelioma in the studies included were sensitivity
0.64 (95% confidence interval 0.61e0.68), specificity 0.89 (0.88e0.90), positive likelihood ratio
7.10 (4.44e11.35), negative likelihood ratio 0.39 (0.31e0.48), and diagnostic odds ratio 19.35
(10.95e34.17).
Conclusions: Serum SMRP determination plays a role in the diagnosis of malignant mesothe-
lioma. The results of SMRP assays should be interpreted in parallel with clinical findings and
the results of conventional tests.
ª 2009 Elsevier Ltd. All rights reserved.of Respiratory Diseases, Union Hospital, Tongji Medical College, Huazhong University of Science and
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Malignantmesothelioma(MM) is anaggressive tumorof serosal
surfaces, suchas thepleuraand theperitoneum,and isusually
associated with previous exposure to asbestos.1 Patients with
pleural MM generally present with shortness of breath and
chest pain, and those with peritoneal MM with abdominal
swelling. The clinical signs of MM are unspecific, but MM is
usually associated with the presence of exudative effusions.
Finding a diagnostic marker for MM is a challenging
endeavor. No unique molecule has been shown to reliably
define MM from benign mesothelium or metastatic carci-
nomas,evenbyprofiling theexpressionof tensof thousandsof
genes on mesothelioma tissues using.2 Immunohistochemical
diagnosis of epithelioid mesothelioma in pleural biopsy or
surgically resected specimens has been actively pursued,
using markers such as podoplanin, calretinin, WT-1, cytoker-
atin 5, thrombomodulin, and mesothelin.3 Some of these
markers have indeedbeenhelpful for confirming thediagnosis
of MM and distinguishing between MM and adenocarcinoma.
Mesothelin is a 40 kDa cell surface glycoprotein that is
highly expressed in MM, pancreatic cancers, ovarian
cancers, and some other cancers.4 Mesothelin is synthe-
sized as a precursor 69 kDa protein and forms two proteins,
the membrane-bound mesothelin and a soluble megakar-
yocyte potentiating factor.4 Although mesothelin is bound
to cell membrane, a circulating form termed soluble mes-
othelin has been reported to be related to abnormal
splicing events leading to synthesis of a secreted protein
and to an enzymatic cleavage from membrane-bound
mesothelin.5 It has been well documented that the soluble
mesothelin-related peptides (SMRPs), including both
soluble mesothelin and soluble megakaryocyte potentiating
factor, have been found in human serum.2 Actually, the
diagnostic accuracy of SMRP detections for MM has been
extensively studied, but the exact role of these detections
needs to be elucidated. We performed the present meta-
analysis to establish the overall diagnostic accuracy of the
measurement of SMRPs for diagnosing MM.
Methods
Search strategy and study selection
We searched Embase, Ovid, Web of Science, Cochrane data-
base, and Medline (using PubMed as the search engine) to
identify suitable studies until March 8, 2008; no lower date
limit was applied. Articles were also identified by use of the
related-articles function in PubMed. References of articles
identified were also searched manually. The search terms
were ‘‘mesothelin’’, ‘‘soluble mesothelin-related peptides/
SMRP’’, ‘‘megakaryocyte potentiating factor/MPF’’, ‘‘meso-
thelioma’’, ‘‘sensitivity and specificity’’, and ‘‘accuracy’’.
Although no language restrictions were imposed initially, for
the full-text review and final analysis our resources only
permitted review of English articles. Conference abstracts
wereexcludedbecause of the limiteddatapresented in them.
A studywas included in themeta-analysis when it provided
SMRPvalues for both sensitivity and specificity of thediagnosis
ofMM.The studies including at least 10 serum specimenswere
selected in the study, since very small studies may bevulnerable to selection bias. Publications with evidence of
possible overlap of patients with other studies were discussed
byL.L.,H.Z.S., andQ.L.L., andonly thebest-quality studywas
used. Two reviewers (L.L. and H.Z.S.) independently judged
study eligibility while screening the citations. Disagreements
were resolved by consensus.
Data extraction and quality assessment
The final set of English articles was assessed independently
by two reviewers (L.L. and H.Z.S.). Data retrieved from the
reports included author, publication year, participant
characteristics, test methods, sensitivity and specificity
data, cut-off value and methodological quality.
For each study, the following characteristics of study
design were also retrieved: (1) cross-sectional design (versus
case-control design); (2) consecutive or random sampling of
patients; (3) blinded interpretation of determination and
reference standard results; and (4) prospective data collec-
tion. If no data on the above criteria were reported in the
primary studies, we requested the information from the
authors. If the authors did not respond to our letters, the
‘‘unknown’’ items were treated as ‘‘No’’. In addition, we
assessed the methodological quality of the studies using
guidelines published by the STARD (standards for reporting
diagnostic accuracy, maximum score 25) initiative6 (i.e.,
guidelines that aim to improve the quality of reporting in
diagnostic studies) and the QUADAS (quality assessment for
studies of diagnostic accuracy, maximum score 14) tool7 (i.e.,
appraisal by use of empirical evidence, expert opinion, and
formal consensus to assess the quality of primary studies of
diagnostic accuracy).
Statistical analyses
Weusedstandardmethodsrecommendedformeta-analysesof
diagnostic test evaluations.8 Analyses were performed using
two statistical software programs (Stata, version 8.2; Stata
Corporation; College Station, TX; and Meta-DiSc for Windows;
XI Cochrane Colloquium; Barcelona, Spain). We computed the
followingmeasures of test accuracy for each study: sensitivity,
specificity, positive likelihood ratio (PLR), negative likelihood
ratio (NLR), and diagnostic odds ratio (DOR).
The analysis was based on a summary receiver operating
characteristic (SROC) curve.8,9 The sensitivity and speci-
ficity for the single test threshold identified for each study
were used to plot an SROC curve.9,10 We convert the true
positive rate (TPR) and false positive rate (FPR) from each
study to their logistic transforms. The method is based on
the principle that there is a linear relationship between
logit (TPR) and logit (FPR) where, using natural logs,
logitðTPRÞZlogðTPR=½1 TPRÞ and logitðFPRÞ
ZlogðFPR=½1 FPRÞ:
To estimate an SROC curve, we use the linear model:
DZaþ bS
where DZ logit (TPR) logit (FPR), SZ logit (TPR)þ logit
(FPR), aZ intercept, bZ regression coefficient of S.
The model can be transformed back to the conventional
axes of TPR against FPR, with SROC curves drawn only over
the range of the data.
Table 1 Summary of mesothelin studies included.a
Study Subjects, no Cut-off Test results Quality score
TP FP FN TN STARD QUADAS
Robinson et al.14 272 0.218 OD 37 10 7 218 16 11
Onda et al.15 126 0.034 OD 51 0 5 70 11 9
Scherpereel et al.16 83 0.93 nM 48 4 12 19 14 10
Scherpereel et al.16 90 1.85 nM 35 8 25 22 14 10
Beyer et al.17 1086 1.5 nM 46 66 42 932 16 12
Creaney et al.18 233 2.5 nM 56 2 61 114 13 11
Cristaudo et al.19 714 1.0 nM 73 149 34 458 14 9
Di Serio et al.20 116 1.5 nM 16 7 8 85 14 12
Amati et al.21 170 1.9 nM 16 15 6 133 12 9
Shiomi et al.22 293 5.6 nM 28 17 11 237 20 13
Iwahori et al.23 156 123.7 ng/ml 11 8 16 121 14 11
van den Heuvel24 229 1.3 nM 44 22 29 134 17 12
a ODZ optical density; TPZ true positive; FPZ false positive; FNZ false negative; TNZ true negative; STARDZ standards for
reporting diagnostic accuracy; QUADASZ quality assessment for studies of diagnostic accuracy.
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can be fit using conventional least squares methods (after
adding 0.5 to each cell of the cross-classification of test and
reference standard to deal with the possibility of zero cells)
unweighted, i.e. giving equal weights to each study, or
weighted by the inverse of the variance of D. A random-
effects model was used to calculate the average sensitivity,
specificity and the other measures across studies.11,12
We used the Chi-square and Fisher’s exact tests to
detect statistically significant heterogeneity across studies.
Since publication bias is of concern for meta-analyses of
diagnostic studies, we tested for the potential presence of
this bias using funnel plots and the Egger test.13Results
After independent review, 20 publications determining
serum concentrations of SMRPs in patients with MM were
considered to be eligible for inclusion in the analysis.14e33Figure 1 Forest plot of estimates of sensitivity and specificity for
The point estimates of sensitivity and specificity from each study ar
Numbers indicate the reference numbers of studies cited in the reOf these publications, 1 was excluded because it recruited
less than 10 patients in one of study groups,25 3 were
excluded because they did not allow the calculation of
sensitivity or specificity,26e28 5 were excluded because the
same authors published several reports on the same
patients, and only the best-quality study was consid-
ered.29e33 Subsequently, 11 publications 14e24 were avail-
able for analysis of diagnosis accuracy of SMRPs in MM. We
noted that eight publications dealt with soluble mesothe-
lin,14,16e21,24 and the remaining three publications dealt
with soluble megakaryocyte potentiating factor.15,22,23 In
the study by Scherpereel et al.,16 the authors compared
SMRP concentrations in MM patients with those in asbestos
exposed-patients with benign pleural lesions and with
patients with pleural metastasis of carcinomas separately,
using two different cut-off values (0.93 and 1.85 nM,
respectively), we thus treated these research data as two
independent studies in the meta-analysis. The clinical
characteristics of these studies, along with STARD and
QUADAS scores, are outlined in Table 1.mesothelin assays in the diagnosis of malignant mesothelioma.
e shown as solid circles. Error bars are 95% confidence intervals.
ference list.
Table 2 Post-test probability of malignant mesothelioma according to pre-test disease prevalence.a
Post-test probability Pre-test disease prevalence
10% 25% 50%
With positive
result (%)
43.8 (32.9e55.6) 70.1 (59.5e78.9) 87.7 (81.6e91.9)
With negative
result (%)
3.8 (2.9e4.8) 11.5 (9.1e13.8) 28.1 (23.1e32.4)
a Values in parentheses are 95% confidence interval estimated by using the lower and upper confidence interval of the random-effects
weighted detection rate and false positive rate estimates.
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The average sample size of the included studies was 297
(range from 83 to 1086), the subjects included 717 patients
with MM and 2851 non-MM. In all studies included in themeta-
analysis, the diagnoses of MM patients studied were made
based on cytological or/and histopathological findings. On the
other hand, the etiology of control groups was quite hetero-
geneous (Appendix Table 1, available online). The method of
determining SMRPs in all studies was enzyme-linked immu-
nosorbent assay.
All required data were provided in the study by Shiomi
et al.22 We contacted the corresponding authors of the
remaining 10 publications through E-mail for obtaining
additional data. Nine authors responded who could provide
additional data for 10 studies. As shown in Appendix Table 2
(available online), in 5 of 12 studies, the study was cross-
sectional design. In 11 studies, all samples were collected
from the consecutive or random selected patients. Four
studies did not report blinded interpretation of SMRP assays
independent of the reference standard. Six studies repor-
ted the study design was prospective. Totally, the quality of
study design and reporting diagnostic accuracy of most
studies were good, since 10 of 12 studies had higher STARD
scores (13) and 9 studies had higher QUADAS scores (10).Figure 2 Summary receiver operating characteristic curves
for mesothelin assays. Each solid circle represents each study in
themeta-analysis. The size of each study is indicated by the size
of the solid circle. The regression summary receiver operating
characteristic curves summarize theoverall diagnosticaccuracy.Diagnostic accuracy
Fig. 1 shows the forest plot of sensitivity and specificity for
12 SMRP assays in the diagnosis of MM. The sensitivity
ranged from 0.41 to 0.91 (pooled 0.64, 95% CI 0.61e0.68),
while specificity ranged from 0.73 to 1.00 (pooled 0.89, 95%
CI 0.88e0.90). We also noted that PLR was 7.10 (95% CI
4.44e11.35), NLR was 0.39 (95% CI 0.31e0.48), and DOR
was 19.35 (95% CI 10.95e34.17). X2 values of sensitivity,
specificity, PLR, NLR, and DOR were 58.08, 168.07, 105.51,
44.65, and 53.09, respectively, with all p< 0.001, indi-
cating a significant heterogeneity between studies.
Post-test probability of MM was estimated by: post-test
probabilityZ post-test odds/(1 post-test odds), where
post-test oddsZ (prevalence/[1 prevalence]) likelihood
ratio. As shown in Table 2, when pre-test probability of MM is
10% (ahypothetical low-riskpatient,which is theapproximate
variation in the reported studies) and when SMRP result is
positive, estimated post-test probability is 43.8%. A negative
test result practically excludes MM (post-test probability,
3.8%).Forapatientwith25%pre-test risk, apositivetest result
increases theprobability to70.1%.TheabsenceofhigherSMRP
concentration decreases the disease probability to 11.5%. For
a high-risk patient (pre-test probability, 50%), the post-test
probability of MM is 87.7%.Figure 3 Funnel graph for the assessment of potential
publication bias in mesothelin assays. The funnel graph plots
the log of the diagnostic odds ratio (DOR) against the standard
error of the log of the DOR (an indicator of sample size). Each
solid circle represents each study in the meta-analysis. The
line in the centre indicates the summary DOR. The Egger test
for publication bias was significant (pZ 0.018).
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showing TPRs versus FPRs from individual studies are shown in
Fig. 2. As a global measure of test efficacy we used the
intersection point of the SROC curve with a diagonal line from
the left upper corner to the right lower corner of the ROC
space, which corresponds to the highest common value of
sensitivity and specificity for the test. This point does not
indicate the only or even the best combination of sensitivity
and specificity for a particular clinical setting, but represents
an overall measure of the discriminatory power of a test. Our
data showed that the SROC curve is not positioned near the
desirable upper left corner of the SROC curve, and that the
maximumjoint sensitivityand specificitywas0.76 (SEM,0.05);
while area under curve (AUC) was 0.82 (SEM, 0.06), indicating
level of overall accuracy was not as high as expected.
Appendix Table 3 (available online) shows the overall
diagnostic accuracy of serum SMRP for differential diagnosis of
patients with MM and healthy subjects, as well as of patients
with MM and those with the other pulmonary diseases. Based
on thecomparisonof sensitivity, specificity, PLR,NLR,DORand
AUC, the overall accuracy of SMRP determination for the
diagnosisofMMseemedtobesomehowbetterwhencomparing
only healthy people to MM. On the other hand, the differential
diagnostic role of SMRP was not so good when comparison was
made between MM and other pulmonary diseases.
Publication bias
Evaluation of publication bias showed that the Egger test
was significant (pZ 0.018). The funnel plots for publication
bias also show some asymmetry (Fig. 3). These results
indicate a potential for publication bias.
We did not use STARD and QUADAS scores to perform the
meta-regression analysis to assess the effect of study quality
on relative DOR of SMRP in the diagnosis of MM due to limited
numbers of the studies included. Because of the same
reason, we could not explore whether or not study design
such as blinded, cross-sectional, consecutive/random and
prospective design affect diagnostic accuracy, either.
Discussion
In the present meta-analysis, our results indicate that deter-
mining concentrations of serum SMRPs produce consistent
results with relative high specificity 0.89 (95% CI 0.88e0.90);
the summary estimate of sensitivity, however, was only 0.64
(95% CI 0.61e0.68), showing that sensitivity estimates were
quite low, andweremorevariable than specificity. Thesedata
suggest that SMRPdeterminationmight be somehowhelpful in
confirming (ruling in) MM. However, these tests maximize
specificity at the cost of sensitivity, and this trade-off has
significant clinical implications. By contrast with the higher
specificity, SMRPs had low sensitivity that was not sufficiently
low to exclude non-MMwhen a patient’s SMRP concentrations
are lower than the cut-off values.
The pre-test probability of MM should be considered in
interpreting SMRP results for management decisions. Medical
history, physical examination, radiographic evaluation, thor-
acentesis or closed pleural biopsy1 may help determine the
pre-test probability. Our estimate of post-test probability has
considerable uncertainty. When the predicted probability ofMM is low (10%), negative SMRP result might be somehow
helpful for ruling out MM; however, positive result is incon-
clusive. When the pre-test risk is quite high (50%), further
diagnostic procedures are unavoidable for documentation or
exclusion of MM. In these cases, SMRPs are probably mean-
ingful only for high-risk patients who do not agree to biopsy; if
SMRP results are positive.
Unlike a traditional ROC plot that explores the effect of
varying thresholds (cut points for determining test positives)
on sensitivity and specificity in a single study, each data point
in the SROC plot represents a separate study. The SROC curve
presents a global summaryof testperformance, and shows the
trade-off between sensitivity and specificity. The results of
analysis based SROC curve showed the maximum joint sensi-
tivity and specificity was 0.76; while AUC was 0.82, indicating
level of overall accuracy was not as high as expected.
The DOR is a single indicator of test accuracy34 that
combines the data from sensitivity and specificity into a single
number. The DOR of a test is the ratio of the odds of positive
test results in the diseased relative to the odds of positive test
results in the non-diseased. The value of a DOR ranges from
0 to infinity, with higher values indicating better discrimina-
tory test performance (higher accuracy). A DOR of 1.0 indi-
cates that a test does not discriminate between patients with
the disorder and those without it. In the present meta-anal-
ysis, we have found that the mean DOR was 19.35, indicating
that SMRP assays seemed to be helpful in the diagnosis of MM.
The diagnostic accuracy of SMRP determination for MM seems
to be similar to those of conventional tests such as cytological
examination e high specificity and low sensitivity. This simi-
larity might make SMRP determination less useful in practice
because theydonothave testproperties that complement the
properties of conventional tests.
Since theSROCcurveand theDORarenot easy to interpret
and use in clinical practice, and since likelihood ratios are
considered more clinically meaningful,35,36 we also pre-
sented both PLR and NLR as our measures of diagnostic
accuracy. Likelihood ratios of greater than 10 or less than 0.1
generate large and often conclusive shifts from pre-test to
post-test probability (indicating high accuracy).33 A PLR
value of 7.10 suggests that patients with MM have about 7-
fold higher chance of being SMRP assay-positive compared
with patients without MM, and this was not high enough for
the clinical purpose. On the other hand, NLR was found to be
0.39 in the present meta-analysis. If the SMRP assay result
was negative, the probability that this patient has MM is 39%,
which is not low enough to rule out MM.
An important strength of our study was its comprehensive
search strategy. Screening, study selection, and quality
assessmentweredone independently and reproduciblyby two
reviewers. We reduced the problem of missing data by con-
tacting authors.Wealsoexploredheterogeneity andpotential
publication bias in accordance with published guidelines. Our
meta-analysis had several limitations. Exclusion of confer-
ence abstracts may have led to publication bias, which may
also be introduced by inflation of diagnostic accuracy esti-
mates since studies that report positive results aremore likely
to be accepted for publication. Indeed, we observed a publi-
cation bias in the present meta-analysis.
It should be mentioned that the way of diagnosing MM was
quite heterogeneous among the studies included, and some
MM patients were diagnosed just based on the cytological
154 L. Luo et al.findings. The current International Panel of pathologists does
not recommend based on cytological samples alone because
of the high risk of diagnostic error.37 Thoracoscopy with
multiple biopsies is preferred, allowing a diagnosis in more
than 90% of cases. In all studies but not the one reported by
Creaney et al.,18 the epithelioid subtype of MM was the most
common pathological type. Totally, 57.2% (410/717) MM were
epithelioid subtype (ranged from 29.9% to 100%). Analysis in
terms of histologic type has shown that serum levels of SMRPs
were significantly elevated in epithelioid subtype MM than
other types.14,16,22 This could explain partly the quite low
sensitivity of the marker in MM diagnosis. On the other hand,
control groups were very heterogeneous from one study to
another and might also in part modify the marker perfor-
mances. All these elements suggest to precise what could be
the target population to assess the serum SMRP values in MM
diagnosis, and this requires further research in the future.
In conclusion, serum SMRP determination plays a role in
the diagnosis of malignant mesothelioma. The results ofAppendix Table 1 The characteristics of subjects studied.
Study/year MM patients Non-MM
Robinson et al.14 Epithelioid type (nZ 25) Health
Sarcomatoid type (nZ 4) Health
Other or not specified (nZ 15) Patient
Patient
Patient
Onda et al.15 Epithelioid type (nZ 56) Health
Scherpereel et al.16,* Epithelioid type (nZ 55) Patient
Sarcomatoid type (nZ 6) Patient
Other or not specified (nZ 13)
Beyer et al.17 Epithelioid type (nZ 59) Health
Sarcomatoid type (nZ 8) Patient
Other or not specified (nZ 21) Patient
Creaney et al.18 Epithelioid type (nZ 35) Health
Sarcomatoid type (nZ 15) Patient
Other or not specified (nZ 67) Patient
Cristaudo et al.19 Epithelioid type (nZ 72) Health
Sarcomatoid type (nZ 10) Patient
Other or not specified (nZ 25) Patient
Di Serio et al.20 Epithelioid type (nZ 20) Health
Sarcomatoid type (nZ 2) Patient
Other or not specified (nZ 2)
Amati et al.21 Epithelioid type (nZ 11) Health
Sarcomatoid type (nZ 6) Subjec
Other or not specified (nZ 5)
Shiomi et al.22 Epithelioid type (nZ 21) Patient
Sarcomatoid type (nZ 9) With a
Other or not specified (nZ 9) Patient
Others
Iwahori et al.23 Epithelioid type (nZ 13) Health
Sarcomatoid type (nZ 3) Health
Other or not specified (nZ 11) Patient
Patient
Van den Heuvel24 Epithelioid type (nZ 43) Health
Sarcomatoid type (nZ 10) Patient
Other or not specified (nZ 20)
* The numbers mean the numbers of recruited patients. MMZmaliSMRP assays should be interpreted in parallel with clinical
findings and the results of conventional tests.
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s with inflammatory non-pleural lung disease (nZ 92)
s with non-MM pleural diseases (nZ 38)
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y controls (nZ 70)
s with benign asbestos-related pleural diseases (nZ 28)
s with pleural metastasis of carcinomas (nZ 35)
y controls (nZ 409)
s with non-MM malignancy (nZ 412)
s with non-malignant conditions (nZ 177)
y controls with asbestos exposure (nZ 33)
s with benign asbestos-related diseases (nZ 53)
s with benign pleural effusions (nZ 30)
y controls (nZ 262)
s with benign respiratory diseases (nZ 130)
s with lung cancer (nZ 215)
y controls with asbestos exposure (nZ 26)
s with asbestos-related diseases (nZ 66)
y controls without asbestos exposure (nZ 54)
ts with asbestos exposure (nZ 94)
s with benign asbestos-related diseases and healthy controls
sbestos exposure (nZ 201)
s with lung cancer (nZ 45)
(nZ 8)
y controls without asbestos exposure (nZ 38)
y controls with asbestos exposure (nZ 9)
s with lung cancer (nZ 47)
s with other cancers (nZ 35)
y controls (nZ 50)
s with lung cancer (nZ 106)
gnant mesothelioma.
Appendix Table 2 Characteristics of included mesothelin studies.*
Study MM Patients (%) Cross-sectional design Consecutive or random Blinded design Prospective
Robinson et al.14 16.2 No Yes Yes Yes
Onda et al.15 44.4 No Yes No No
Scherpereel et al.16 72.3 Yes Yes Yes Yes
Scherpereel et al.16 66.7 Yes Yes Yes Yes
Beyer et al.17 8.1 Yes Yes Yes No
Creaney et al.18 50.2 No Yes Yes Yes
Cristaudo et al.19 15.0 Unknown Yes Unknown Unknown
Di Serio et al.20 20.7 Yes Yes Yes No
Amati et al.21 12.9 Unknown Yes Unknown Yes
Shiomi et al.22 13.3 No In part Yes Yes
Iwahori et al.23 17.3 Yes Yes No No
Van den Heuvel24 31.9 Unknown Yes Yes No
* MMZmalignant mesothelioma.
Appendix Table 3 Pooled results of diagnostic accuracy of soluble mesothelin-related peptides for malignant mesothelioma
between subpopulation.
MM versus
healthy controls
MM versus
other lung diseases
Numbers of studies 7 7
Sensitivity (95% CI) 0.64 (0.59e0.68) 0.61 (0.57e0.66)
Heterogeneitya (p) 50.54 (<0.0001) 34.41 (<0.0001)
Specificity (95% CI) 0.92 (0.90e0.94) 0.90 (0.87e0.92)
Heterogeneity* (p) 113.63 (<0.0001) 54.98 (<0.0001)
PLR (95% CI) 13.66 (4.63e40.27) 6.15 (3.17e11.90)
Heterogeneity (p) 65.37 (<0.0001) 47.32 (<0.0001)
NLR (95% CI) 0.35 (0.26e0.48) 0.41 (0.31e0.55)
Heterogeneity (p) 35.62 (<0.0001) 28.78 (<0.0001)
DOR (95% CI) 46.21 (6.25e61.52). 24.74 (10.50e58.28)
Heterogeneity (p) 36.21 (<0.0001) 36.96 (<0.0001)
AUC (SEM) 0.85 (0.05) 0.77 (0.11)
* Q value MMZmalignant mesothelioma; CIZ confidence interval; PLRZ positive likelihood ratio; NLRZ negative likelihood ratio;
DORZ diagnostic odds ratio; AUCZ area under curve; SEMZ standard error of mean.
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